Neurocrine Biosciences
NBIX
NBIX
508 hedge funds and large institutions have $10.3B invested in Neurocrine Biosciences in 2023 Q3 according to their latest regulatory filings, with 89 funds opening new positions, 157 increasing their positions, 197 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 11 → 11 (0)
0.01% less ownership
Funds ownership: 93.86% → 93.85% (-0.01%)
20% less repeat investments, than reductions
Existing positions increased: 157 | Existing positions reduced: 197
Holders
508
Holding in Top 10
11
Calls
$71.2M
Puts
$54.7M
Top Buyers
| 1 | +$278M | |
| 2 | +$51.4M | |
| 3 | +$50.4M | |
| 4 |
Millennium Management
New York
|
+$47M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$36M |
Top Sellers
| 1 | -$99.8M | |
| 2 | -$95.5M | |
| 3 | -$64.1M | |
| 4 |
Man Group
London,
United Kingdom
|
-$59.5M |
| 5 |
AC
Armistice Capital
New York
|
-$48.8M |